New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate To Severe Plaque Psoriasis In Children And Adolescents
"Moderate to severe plaque psoriasis is a chronic disease of the immune system that can significantly impact many aspects of the daily lives of children and teens," says Amy Paller, M.D., study investigator and Professor and Chair of Dermatology, Northwestern University School of Medicine. "These etanercept data are encouraging and reinforce the importance of continuing to investigate treatment options that may help this particularly vulnerable patient population manage their disease."
During the 48-week study, the percentage of patients achieving 75 percent or greater disease improvement from baseline, as measured by the standard Psoriasis Area and Severity Index (PASI 75), was used to evaluate the efficacy of ENBREL in patients between 4 and 17 years old. The primary efficacy endpoint was PASI 75 at week 12. There were 106 patients initially randomized to receive ENBREL and 105 patients randomized to receive placebo.
- At week 12, which was the conclusion of the double-blind, placebo-controlled portion of the study, 57 percent (n=60) of pediatric patients treated with ENBREL achieved PASI 75, compared with 11 percent (n=12) of pediatric patients who received placebo (p
Nou studiu rapoarte de Enbrel (R) (etanercept) semnificativ îmbunãtãþite moderatã pânã la severã, psoriazis în plãci în copii ºi adolescenþi - New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate To Severe Plaque Psoriasis In Children And Adolescents - articole medicale engleza - startsanatate